NCT00965718View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

Activated T lymphocyte

Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.

Trial Locations (1)

Unknown

Yonsei medical center, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY